Babcock Genetics, Inc.

Belkins
Babcock Genetics, Inc. is a leading supplier of swine genetics to the United States commercial industry. By utilizing cutting edge research methods, superior swine genetics, and a closed herd system, Babcock supplies its customers with a genetic base with a high probability for profitability. Babcock is an innovative company that is committed to all facets of the pork industry in addition to its own success. Minimum disease risk, excellent reproductive performance, growth rate, feed efficiency, and pork quality best describe Babcock Genetics.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

TAVOTEK BIOTHERAPEUTICS ANNOUNCES COMPLETION OF ROUND B FINANCING WITH $35 MILLION

Tavotek | November 19, 2021

news image

Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addit...

Read More

GSK STARTS PHASE 2/3 STUDY OF COVID-19 ANTIBODY TREATMENT WITH VIR BIOTECHNOLOGY

GlobeNewswire | September 01, 2020

news image

-Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc announced that the first patient was dosed last week in a Phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalization. The aim of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study, which will enroll approximatel...

Read More

FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO SUPPORT COVID-19 VACCINE CANDIDATE MANUFACTURING

FUJIFILM Diosynth Biotechnologies | July 28, 2020

news image

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.The Biomedical Advanced Research and Development Auth...

Read More

CELL AND GENE THERAPY

BOSTON LABS AND GERMFREE LAUNCH MOBILE CELL AND GENE THERAPY (CGT) MANUFACTURING PLATFORM

BOSTON LABS | September 23, 2021

news image

Clinical logistics and life science manufacturing leaders Boston Labs and Germfree Laboratories Inc. announced their partnership to launch a new network of mobile CGT manufacturing facilities. The two companies are combining deep logistics, CGT manufacturing expertise and mobile cleanroom technology to deliver CGT point-of-care contract manufacturing services. The CGT mobile manufacturing platform will launch in Boston, MA in the fourth quarter of 2021 and will scale to a network ...

Read More

MEDTECH

Tavotek | November 19, 2021

news image

TAVOTEK BIOTHERAPEUTICS ANNOUNCES COMPLETION OF ROUND B FINANCING WITH $35 MILLION

Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addit...

Read More

GlobeNewswire | September 01, 2020

news image

GSK STARTS PHASE 2/3 STUDY OF COVID-19 ANTIBODY TREATMENT WITH VIR BIOTECHNOLOGY

-Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc announced that the first patient was dosed last week in a Phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalization. The aim of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study, which will enroll approximatel...

Read More

FUJIFILM Diosynth Biotechnologies | July 28, 2020

news image

FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO SUPPORT COVID-19 VACCINE CANDIDATE MANUFACTURING

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.The Biomedical Advanced Research and Development Auth...

Read More

CELL AND GENE THERAPY

BOSTON LABS | September 23, 2021

news image

BOSTON LABS AND GERMFREE LAUNCH MOBILE CELL AND GENE THERAPY (CGT) MANUFACTURING PLATFORM

Clinical logistics and life science manufacturing leaders Boston Labs and Germfree Laboratories Inc. announced their partnership to launch a new network of mobile CGT manufacturing facilities. The two companies are combining deep logistics, CGT manufacturing expertise and mobile cleanroom technology to deliver CGT point-of-care contract manufacturing services. The CGT mobile manufacturing platform will launch in Boston, MA in the fourth quarter of 2021 and will scale to a network ...

Read More